Facility and Building System Upgrades Support for the Howard T. Ricketts Biocontainment Laboratory

为 Howard T. Ricketts 生物防护实验室提供设施和建筑系统升级支持

• 批准号: 10394614
• 负责人: Erin June Adams
• 金额: $ 329.97万
• 依托单位: UNIVERSITY OF CHICAGO
• 依托单位国家: 美国
• 财政年份: 2021
• 资助国家: 美国
• 起止时间: 2021-09-16 至 2025-02-28
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10394614
• 关键词: 2019-nCoV; Anthrax disease; Bacillus; Biomedical Research; Brucella; Centers for Disease Control and Prevention (U.S.); Chicago; County; Coxiella; Department of Energy; Development; ESKAPE pathogens; Ensure; Equipment; Goals; Humidity; Illinois; Infectious Agent; Influenza; Institution; Laboratories; Life; Microbiology; Operations Research; Organism; Pathogenicity; Plague; Regulation; Research; Research Support; Rickettsia; Site; Students; Surveillance Program; Swelling; System; Temperature; Testing; Training Programs; Universities; Yersinia; emerging pathogen; experimental study; laboratory experiment; methicillin resistant Staphylococcus aureus; new technology; novel therapeutics; novel vaccines; pathogen; pathogenic virus; pressure; programs; research facility

Project Summary/Abstract The Howard Taylor Ricketts Laboratory (HTRL) is a state-of-the-art Regional Biocontainment Laboratory on the Argonne National Laboratory (ANL) campus in DuPage County, Illinois. Located twenty-five miles southwest from the University of Chicago campus, ANL is a federally (Department of Energy) owned site operated by the University of Chicago (UCHICAGO LLC). HTRL is a CDC certified facility owned by the University of Chicago and operated by the Department of Microbiology. Biosafety training and surveillance program involving classroom and laboratory activities ensures that staff, students and fellows comply with state and federal regulations to safely operate facilities and experiments with RG2, RG3 and Select Agent pathogens. The HTRL construction was completed in 2008. Over the last 13 years, the HTRL has hosted research programs studying the bacterial species Yersinia, Brucella, Coxiella, Rickettsia, Bacilli, MRSA and other ESKAPE organisms, as well as viral pathogens including low and highly pathogenic influenza, DENGUE and more recently SARS-CoV2. The facility currently hosts research program on Plague, Anthrax and MRSA, as well as a Core Research Facility for SARS-CoV2. The HTRL is the largest A-BSL3 holding facility in the region and regularly supports research from consortium institutions including UIC, Northwestern U and Loyola U. The HTRL is fulfilling its goal as a biomedical research facility that can rapidly respond to research needs and support biomedical research on emerging and re-emerging pathogens, discovery and testing of new therapeutics and vaccines. The building has been maintained in excellent working conditions and has been in constant use since its construction. However, with the swelling demands for BSL3 and ABSL3 space and research expertise, the development of new technologies for the study of infectious agents, this proposal is a request (i) to upgrade system components necessary to maintain biocontainment, temperature/humidity/pressurization requirements, and safe research operations, and (ii) to replace research equipment that have either outlived the intended useful life or no longer meet facility requirements.

项目摘要/摘要 霍华德·泰勒·里基茨实验室(HTRL)是最先进的区域生物遏制技术 实验室位于伊利诺伊州杜佩奇县的阿贡国家实验室(ANL)园区。 ANL位于芝加哥大学校区西南25英里处，是一所联邦大学 (能源部)由芝加哥大学(UChicago LLC)运营的网站。 HTRL是由芝加哥大学拥有的CDC认证机构，由 微生物学系。涉及课堂的生物安全培训和监测计划 实验室活动确保工作人员、学生和研究员遵守州和联邦 使用RG2、RG3和选择试剂安全操作设备和实验的规则 病原体。高铁的建设于2008年完成。在过去的13年里，高铁 主持了研究耶尔森氏菌、布鲁氏菌、柯克斯氏菌、 立克次体、芽孢杆菌、耐甲氧西林金黄色葡萄球菌和其他ESKAPE生物，以及包括 低致病性和高致病性流感、登革热以及最近的SARS-CoV2。该设施 目前主持关于鼠疫、炭疽和耐甲氧西林金黄色葡萄球菌的研究计划以及核心研究 SARS-CoV2的设施。高铁是区内最大的A-BSL3持有设施，以及 定期支持包括UIC、西北大学和 洛约拉大学的HTRL正在实现其作为生物医学研究机构的目标，该机构可以迅速 响应研究需求，支持新兴和再崛起的生物医学研究 病原体、新疗法和疫苗的发现和测试。这座建筑已经被 保持在良好的工作条件下，自建造以来一直在使用。 然而，随着对BSL3和ABSL3空间和研究专业知识的需求不断膨胀， 发展研究传染病病原体的新技术，这项建议是一项要求(一) 为了升级维持生物遏制所需的系统组件， 温度/湿度/加压要求和安全研究作业；以及(Ii) 更换已超过预期使用寿命或不再符合要求的研究设备 设施要求。